■免疫检查点抑制剂(ICIs)改变了非小细胞肺癌(NSCLC)的治疗。然而,抵抗是不可避免的。疾病进展模式,序贯治疗,和超过ICI耐药性的预后尚未完全了解。
我们回顾性分析了2016年1月至2020年1月在浙江省肿瘤医院接受ICI治疗的IV期非小细胞肺癌患者,这些患者在接受免疫治疗至少稳定3个月(至少2个周期)后病情进展。在以前的报告中定义了寡进展和系统进展。主要结局指标为无进展生存期(PFS),第二PFS(PFS2),总生存率(OS)。使用Kaplan-Meier方法绘制存活曲线。Cox比例风险模型用于多变量分析。
■共1,014例NSCLC患者接受了免疫治疗。其中,208例NSCLC患者纳入本回顾性研究。估计的PFS,PFS2和OS为6.3个月(95%CI5.6-7.0个月),10.7个月(95%CI10.1-12.7个月),和21.4个月(95%CI20.6-26.4个月),分别。抵抗之后,55.3%(N=115)患者出现了少进展,和44.7%(N=93)的全身进展。对于全身性进展的患者,化疗(N=35,37.6%),最佳支持治疗(N=30,32.3%),和单独抗血管生成治疗(N=11,11.8%)是主要的策略.局部放疗(N=38,33.0%)与持续ICIs的组合是在少进展组中最常用的治疗方法。其次是持续的免疫治疗,包括抗血管生成治疗(N=19,16.5%)和仅局部放疗(N=17,14.9%).对于少进展的患者,持续的免疫治疗加局部放疗可导致PFS2明显延长(12.9vs.10.0个月;p=0.006)和OS(26.3与18.5个月,p=0.001)。少进展患者的PFS2和OS优于全身进展患者(PFS2:13.1vs.10.0个月,p=0.001;OS:25.8vs.19.1个月,p=0.003)。
■免疫疗法获得性耐药后的主要进展模式是少进展。在晚期NSCLC患者中,局部放疗与持续免疫疗法超越少许进展是可行的,并导致PFS2和OS延长。
UNASSIGNED: Immune checkpoint inhibitors (ICIs) have changed the management of non-small cell lung cancer (NSCLC). However, resistance is inevitable. The disease progression patterns, sequential treatment, and prognosis beyond ICI resistance are not completely understood.
UNASSIGNED: We retrospectively analyzed stage IV NSCLC patients who underwent ICI treatment at Zhejiang Cancer Hospital between January 2016 and January 2020 and who suffered disease progression after at least stable disease on immunotherapy for more than 3 months (at least two cycles).
Oligoprogression and systematic progression were defined as previous reports. The main outcome measures were progression-free survival (PFS), second PFS (PFS2), and overall survival (OS). Survival curves were plotted using the Kaplan-Meier method. The Cox proportional hazards model was used for multivariate analysis.
UNASSIGNED: Totally 1,014 NSCLC patients were administered immunotherapy. Of them, 208 NSCLC patients were included in this retrospective study. The estimated PFS, PFS2 and OS were 6.3 months (95% CI 5.6-7.0 months), 10.7 months (95% CI 10.1-12.7 months), and 21.4 months (95% CI 20.6-26.4 months), respectively. After resistance, 55.3% (N = 115) patients developed
oligoprogression, and 44.7% (N = 93) systemic progression. For patients with systemic progression, chemotherapy (N = 35, 37.6%), best supportive care (N = 30, 32.3%), and antiangiogenic therapy alone (N = 11, 11.8%) were the major strategies. A combination of local radiotherapy (N = 38, 33.0%) with continued ICIs was the most common treatment used in oligoprogression group, followed by continued immunotherapy with antiangiogenic therapy (N = 19, 16.5%) and local radiotherapy only (N = 17, 14.9%). For patients with
oligoprogression, continued immunotherapy plus local radiotherapy can lead to a significantly longer PFS2 (12.9 vs. 10.0 months; p = 0.006) and OS (26.3 vs. 18.5 months, p = 0.001). The PFS2 and OS of patients with
oligoprogression were superior to those of patients with systemic progression (PFS2: 13.1 vs. 10.0 months, p = 0.001; OS: 25.8 vs. 19.1 months, p = 0.003).
UNASSIGNED: The major progression pattern after acquired resistance from immunotherapy is oligoprogression. Local radiotherapy with continued immunotherapy beyond
oligoprogression in responders was feasible and led to prolonged PFS2 and OS in advanced NSCLC patients.